Pomalidomide (Pomalyst)
General information
Class/mechanism: Second-generation immunomodulatory drug (IMiD)--a thalidomide analogue--with antineoplastic activity. Pomalidomide has been shown to inhibit growth and induce apoptosis of hematopoietic tumor cells, enhance natural killer (NK) and T-cell cell-mediated immunity, and suppress monocyte production of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).[1][2][3]
Route: PO
Extravasation: n/a
- Use of Pomalidomide (Pomalyst) requires participation in the Pomalyst REMS program
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Pomalidomide (Pomalyst) package insert[1]
- Pomalidomide (Pomalyst) patient drug information (Chemocare)[4]
- Pomalidomide (Pomalyst) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2/8/2013: FDA approved for treatment of multiple myeloma in patients who received at least two previous therapies including Lenalidomide (Revlimid) and Bortezomib (Velcade) who have progressive disease within 60 days of the completion of the last therapy[1]
Also known as
- Code names: CC4047, CC-4047
- Generic name: 3-amino-thalidomide
- Brand names: Actimid, Ibipolid, Imnovid, Pomalid, Pomalyst